東方集團(600811.SH):控股股東所持1.03億股被司法凍結、3.9億股被司法標記
格隆匯3月3日丨東方集團(600811.SH)公佈,公司於2022年3月2日收到中國證券登記結算有限責任公司上海分公司《股權司法凍結及司法劃轉通知》(2022司凍0302-2號),因山東天商置業有限公司(以下簡稱“山東天商”)與國開東方城鎮發展投資有限公司(以下簡稱“國開東方”)、東方集團有限公司、本公司、先鋒中潤生物科技有限公司合同糾紛一案(以下簡稱“本次合同糾紛案”),公司控股股東東方集團有限公司所持1.03億股無限售流通股被司法凍結,3.9億股無限售流通股被司法標記,上述股權合計4.93億股,佔東方集團有限公司持有本公司股份比例100%,佔公司總股本比例13.27%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.